By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology have been published. According to news reporting from Lodz, Poland, by NewsRx journalists, research stated, "The immune system constitutes an important first-line defence against malignant transformation. However, cancer mediated immunosuppression inactivates the mechanisms of host immune surveillance."
The news correspondents obtained a quote from the research from the University of Lodz, "Cancer cells shut down anti-cancer immunity through direct cell-cell interactions with leukocytes and through soluble factors, establishing an immunosuppressive environment for unimpeded cancer growth. The composition of the immunosuppressive microenvironment in breast tumours is not well documented. To address this question, selected immunosuppressive factors were analyzed in tumour specimens from 33 breast cancer patients after surgery. The mRNA expression of selected genes was quantified in fresh tumour samples. Tumour infiltrating leukocytes were characterized by flow cytometry to identify regulatory T cells, myeloid derived suppressor cells, and type 2 macrophages. Statistical analysis revealed several interesting correlations between the studied parameters and clinical features. Overall, a surprisingly high degree of heterogeneity in the composition of the immunosuppressive environment was found across all breast cancer samples which adds to the complexity of this disease. The influence of the hypoxia inducible factors (HIFs) on the immune microenvironment was also addressed. The level of HIFs correlated with hormone receptor status and the expression of several immunosuppressive molecules."
According to the news reporters, the research concluded: "Targeting HIFs might not only sensitize breast tumours for radiation and chemotherapies but also interfere with cancer immunosuppression."
For more information on this research see: The heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genes. Immunobiology, 2014;219(2):158-165. Immunobiology can be contacted at: Elsevier Gmbh, Urban & Fischer Verlag, Office Jena, P O Box 100537, 07705 Jena, Germany. (Elsevier - www.elsevier.com; Immunobiology - www.elsevier.com/wps/product/cws_home/701769)
Our news journalists report that additional information may be obtained by contacting M. Duechler, Medical Univ Lodz, Clin Oncol Surg, PL-93513 Lodz, Poland. Additional authors for this research include L. Peczek, K. Zuk, I. Zalesna, A. Jeziorski and M. Czyz (see also Oncology).
Keywords for this news article include: Lodz, Poland, Europe, Genetics, Oncology, Immunology, Leukocytes, Blood Cells, Breast Cancer, Immune System, Women's Health
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC